FDA Approves TRANEXAMIC ACID — Eugia US LLC
Eugia US LLC received FDA approval for its ANDA for tranexamic acid intravenous injection (2016), a generic version of the marketed hemostatic agent. This clearance expands generic competition in the IV anti-fibrolytic space, a segment known for high utilization in surgical and trauma settings.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day